• Xometry, Inc. recently completed and priced an underwritten follow-on offering of 2,647,059 Class A common shares at US$85.00 each, raising about US$225.0 million in gross proceeds with an additional 30-day over-allotment option for underwriters.
• By pairing this equity raise with a universal shelf registration for common stock, preferred stock, debt securities, and warrants, Xometry has increased its flexibility to access capital markets for working capital and broader corporate purposes.
• We’ll now examine how Xometry’s US$225 million equity raise and expanded shelf registration could influence its existing growth-focused investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

Xometry Investment Narrative Recap

To own Xometry, you need to believe its AI powered marketplace can turn rapid revenue growth into a sustainable path toward profitability, despite ongoing losses and heavy reinvestment. The US$225 million follow on offering and new shelf registration chiefly affect how Xometry funds that journey, not the core thesis itself. The most immediate catalyst remains execution on fast growing marketplace revenue, while the biggest near term risk is continued equity dilution if profitability stays out of reach.

The follow on equity raise is most closely tied to Xometry’s updated 2026 guidance, which already called for revenue growth in the high 20s percent range and improving marketplace mix. The fresh capital, combined with earlier proceeds from Siemens’ US$50 million share purchase, reinforces the company’s balance sheet ahead of that plan. However, it also sharpens the existing risk that future growth for this capital intensive model may keep coming at the cost of ongoing shareholder dilution.

Yet while growth headlines may look attractive, investors should also be aware that continued share issuance and unproven profitability could...

Xometry's narrative projects $1.2 billion revenue and $52.0 million earnings by 2029. This requires 19.0% yearly revenue growth and a $113.7 million earnings increase from -$61.7 million today.

Uncover how Xometry's forecasts yield a $62.33 fair value, a 25% downside to its current price.

Exploring Other Perspectives

Before this raise, the most optimistic analysts were banking on revenue reaching about US$1.3 billion and earnings near US$100 million, which is far more bullish than consensus and assumes international scaling succeeds despite the hurdles we just discussed. This follow on offering could either support that view or force a rethink, so it is worth comparing these contrasting expectations and deciding which version of Xometry’s future you find more realistic.

Explore 4 other fair value estimates on Xometry - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Xometry research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Xometry research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xometry's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.